World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
35689
World Ranking
16405
National Ranking
206

Overview

Evandro de Azambuja is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on oncology and cancer-related studies.

The scientist's work extends across several subfields, including Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, and Genetics. Their research topics cover a range of areas such as Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Cancer Risks and Factors, Cancer Immunotherapy and Biomarkers, and Chemotherapy-induced cardiotoxicity and mitigation.

Evandro de Azambuja has published extensively with frequent contributions appearing in a number of scientific venues. These include:

  • ESMO Open
  • Annals of Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • European Journal of Cancer

Their collaboration network features several frequent co-authors, among them:

  • Matteo Lambertini
  • Martine Piccart
  • Elisa Agostinetto
  • Marco Bruzzone
  • Guilherme Nader Marta

Recent significant publications include:

  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) (2022), published in European Heart Journal
  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (2021), published in New England Journal of Medicine
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer (2021), published in Annals of Oncology
  • Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020), published in Annals of Oncology
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours (2021), published in Annals of Oncology

Best Publications

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    Gunter von Minckwitz;Marion Procter;Evandro de Azambuja;Dimitrios Zardavas

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

    Luca Gianni;Urania Dafni;Richard D Gelber;Evandro Azambuja

  • Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial

    Roberto Salgado;Carsten Denkert;Christine Campbell;Peter Savas

  • Planning cancer control in Latin America and the Caribbean

    Paul E. Goss;Brittany L. Lee;Brittany L. Lee;Tanja Badovinac-Crnjevic;Kathrin Strasser-Weippl

  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial

    Aron Goldhirsch;Richard D. Gelber;Martine J. Piccart-Gebhart;Evandro De Azambuja

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

    Evandro De Azambuja;Andrew P. Holmes;Martine Piccart-Gebhart;Eileen Holmes

  • Dissecting the Heterogeneity of Triple-Negative Breast Cancer

    Otto Metzger-Filho;Andrew M Tutt;Evandro Azambuja;Kamal S Saini

  • Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

    Thomas Eschenhagen;Thomas Force;Michael S. Ewer;Gilles W. De Keulenaer

  • An update on PARP inhibitors—moving to the adjuvant setting

    Amir Sonnenblick;Evandro de Azambuja;Hatem A. Azim;Martine Piccart

  • Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

    Christian Widakowich;Christian Widakowich;Gilberto de Castro;Evandro de Azambuja;Evandro de Azambuja;Phuong Dinh

  • Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

    Martine Piccart-Gebhart;Eileen Holmes;Jośe Baselga;Evandro De Azambuja

  • Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives

    Felipe Ades;Dimitrios Zardavas;Ivana Bozovic-Spasojevic;Lina Pugliano

  • Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

    Kamal S. Saini;Kamal S. Saini;Sherene Loi;Evandro de Azambuja;Otto Metzger-Filho

  • Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

    M. Colozza;E. Azambuja;F. Cardoso;C. Sotiriou

  • Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

    Marion Procter;Thomas M. Suter;Evandro De Azambuja;Urania Dafni

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Richard D. Gelber
Richard D. Gelber Harvard University
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Marianne Paesmans
Marianne Paesmans Université Libre de Bruxelles
Giuseppe Viale
Giuseppe Viale University of Milan
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Medicine can open doors to a wide range of rewarding healthcare careers. However, not all paths require a traditional medical degree. Many students explore related online degrees that offer flexibility, affordability, and targeted expertise. For example, earning a healthcare administration degree online is a great option for those interested in leadership and management roles within the healthcare sector.

Graduate-level programs are especially valuable. Among the most affordable online mha programs, students can gain crucial skills in healthcare policy, operations, and strategy—often while still working full-time. For those aiming to specialize in nursing, some of the most affordable online dnp programs prepare graduates for advanced practice and leadership positions.

Pharmacy is another in-demand medical field. Choosing the best online pharmacy school can help kickstart a fulfilling career in pharmaceutical care. Exploring these online degree options can be a smart, flexible pathway for those passionate about making a difference in healthcare.

Best Scientists Citing Evandro de Azambuja

Trending Scientists

Recently Published Articles